Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

• Status: RECRUITING
• Trial end date: 2028-01-30

Summary

This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have failed after at least one prior platinum-containing standard regimen and anti-PD-1/PD-L1 therapy.

The four treatment arms include:

1. Ivonescimab monotherapy,

2. Ivonescimab combined with nimotuzumab,

3. Liposomal mitoxantrone plus anti-PD-1 antibody, and

4. Liposomal irinotecan plus S-1.

• Phase: PHASE2

Details

• Lead Sponsor: Ming-Yuan Chen
• Treatments: Immune Checkpoint Inhibitors; irinotecan sucrosofate; nimotuzumab; S 1 (combination)